一分钟看懂
这是一项关于急性髓系白血病的II 期研究，登记的药物或干预包括Azacitidine (AZA)；Venetoclax，当前状态为研究进行中，已停止招募。登记地点显示中国Palma de Mallorca、Badalona、Barcelona、Girona等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Azacitidine (AZA)；Venetoclax · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- University Hospital Son Espases · Palma de Mallorca
- Hospital Son Llatzer · Palma de Mallorca
- Institut Catala D oncologia Badalona · Badalona
- Hospital Del Mar · Barcelona
- Hospital De La Santa Creu I Sant Pau · Barcelona
- Hospital Universitari Vall D Hebron · Barcelona
- Hospital Clinic De Barcelona · Barcelona
- Institut Catala D oncologia Girona · Girona
- Institut Catala D oncologia Hospitalet · L'Hospitalet de Llobregat
- Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida · Lleida
- Hospital Universitari Joan XXIII De Tarragona · Tarragona
- Fundacio Assistencial De Mutua De Terrassa · Terrassa
- Hospital General Universitario Gregorio Maranon · Madrid
- Hospital Clinico Universitario De Valencia · Valencia
公开的入选条件
- 1. Patients must have confirmation of with acute myeloid leukemia (AML) with persistent measurable residual disease (MRD) or MRD reappearance after frontline intensive chemotherapy (including at least one cycle of cytarabine and anthracycline), and prior to al
- 1. In patients with NPM1 mutation, qRT-PCR of NPM1 will be the method used to establish a molecular failure, defined as failure to achieve molecular response after consolidation therapy (NPM1mut/ABL1·100 \> 0.1) or MRD reappearance after molecular respo
- 2. In patients with core-binding factor AML, qRT-BCR of RUNX1-RUNX1T1 and CBFb-MYH11 transcripts will be used. Patients failing to achieve a major MRD reduction after consolidation therapy (i.e., RUNX1-RUNX1T1/ABL1·100\>0.1 or CBFb-MYH11/ABL1·100\&g
- 3. In the remaining cases, an appropriate leukemia-associated immunophenotype (LAIP) measured by multiparameter flow cytometry will be used for MRD surveillance. A cutoff of 0.1% will be used to define MRD positivity.
- 2. Age ≥18 years.
- 3. Without clinical signs of active central nervous system disease.
- 4. Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance status of ≤2 or Karnofsky performance status (KPS) equivalent.
- 5. Patients must have adequate renal function as demonstrated by a calculated creatinine clearance ≥ 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06668558；登记信息更新于 2026-09-17。